IMPT-514 is said to be the only CD19/CD20 CAR T-cell therapy currently in development for multiple sclerosis. Credit: Ocskay Mark/Shutterstock.

ImmPACT Bio has secured investigational new drug (IND) application approval from the US Food and Drug Administration (FDA) for CD19/CD20-targeting chimeric antigen receptor (CAR) T-cell therapy, IMPT-514, which helps to prepare for a clinical trial to treat adult patients with multiple sclerosis (MS).

The company is set to initiate the Phase I dose escalation trial targeting all forms of MS, with the goal of slowing or halting the progression of disability.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The trial aims to assess IMPT-514, which stands out as the sole CD19/CD20 CAR T-cell therapy currently in development for MS.

ImmPACT Bio CEO Sumant Ramachandra said: “IND clearance for our bispecific CAR T-cell therapy in MS marks an exciting achievement that further expands the clinical development of our autoimmune programme.

“As an intended one-time treatment, IMPT-514 has the potential to reset the immune system by depleting a broad range of autoreactive immune cells implicated in the pathogenesis of MS in patients. We expect to dose the first patient in the first half of 2025.”

See Also:

The IMPT-514 therapy uses a bispecific CAR and a 4-1BB costimulatory domain, sharing its CAR construct with IMPT-314, which is being developed for certain types of non-Hodgkin’s lymphoma.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In preclinical studies, the therapy has shown positive results, demonstrating efficient manufacturing even for patients with significant immunosuppression due to autoimmune diseases.

It has also exhibited potent autologous B-cell elimination and a moderate cytokine profile.

ImmPACT Bio chief medical officer Jonathan Benjamin said: “The dual-targeting nature of IMPT-514 offers a unique opportunity to potentially ablate autoreactive B cells and the likely pathogenic CD20-expressing T-cells.

“Moreover, the ability of CAR T-cells to cross the blood-brain barrier (BBB) could potentially overcome the limitations of current disease-modifying therapies, such as anti-CD20 antibodies, that are not effective at crossing the BBB, where potentially pathogenic cells reside.”

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.